Emperra’s ESYSTA® diabetes smartphone app, ESYSTA® Smart Insulin Pen under CE conformity assessment procedure

Emperra GmbH E-Health Technologies, specialized in digital health systems and Tele-diabetology, today announced an important further development of the innovative, integrated telemonitoring product system ESYSTA^® for insulin-dependent diabetes patients. The Bluetooth-enabled ESYSTA^® Smart Insulin Pen, as well as the ESYSTA^® diabetes smartphone app are almost ready for their market launch. The ESYSTA^® smartphone app is also open for and compatible with other conventional Bluetooth-enabled blood glucose meters. Both components are in the last stages of the CE conformity assessment procedure and will be available as an extension of the ESYSTA^® product system on the European market expectedly from late summer 2015.

Data transfer via Bluetooth. The prototype

EMPERRA^® developed the ESYSTA^® Bluetooth Pen for those diabetics, who would like to send their data directly from the ESYSTA^® Insulin Pen to their smartphone. It is equipped with a Bluetooth interface via which it communicates with the also newly developed ESYSTA^® App. Other Bluetooth enabled blood glucose meters can also be linked to the ESYSTA^® app. Further connections, like sensors for continuous glucose measurement, are under development.  All data could be sent by the app to the clearly structured ESYSTA^® portal. The insulin pen as well as the app are currently under the CE conformity assessment procedure and will be available all over Europe shortly.

On this topic, Dr. Christian Krey, CEO of EMPERRA^®, comments:

The further development of the already commercially available insulin-data transferring ESYSTA Smartpen to a Bluetooth enabled insulin pen is a logical step. By the direct transfer of the insulin data to a smartphone, a database is available at all times, that will further simplify the treatment. First diabetes centers and health insurers have already expressed their interest in providing their patients with the  ESYSTA Bluetooth pen.

The ESYSTA^® Bluetooth transmission technology

While the well-known mechanical solution for injection and the tested magnetic sensory for dosage record was adopted from the current ESYSTA^® Pen, the type of data transfer will be adapted to Bluetooth low energy standards. This basically enables the connection to Bluetooth enabled smartphones, computers and even wearables (like smartwatches and measuring instruments for vital signs). The dosing accuracy for insulin of all current manufacturers will furthermore be guaranteed by the ESYSTA^® adapters. Well known features that make life with daily insulin injections easier, like the automatic date and time set up or the global data access to the ESYSTA^® portal solution are of course integrated.

Moving towards highly modern high-tech diabetes management systems, the Potsdam-based medical technology think tank EMPERRA^® takes the next big step. The development of a Bluetooth enabled insulin pen and the corresponding smartphone software will address patients, who prefer the latest technological solutions on mobile devices and would like to use the immediately available data for their self-management.

Dr. Krey says:

Emperra is planning to offer this integrated Bluetooth solution, in compliance with CE standards, as a medical device to the European market late summer and will thereby continue to be the main innovation driver especially for smart insulin pens and integrated diabetes solutions.

The current ESYSTA^® version, that already allows insulin data and blood glucose values to be transferred wirelessly and made visible for the patient and the physician, will still be provided to patients, who prefer easy solutions or are not willing or able to use devices like smartphones or computers. Especially in nursing homes or for elderly diabetics the already in use, short-wave based product system ESYSTA^® has proved tremendous medical effects. ESYSTA^® is already in use in Germany - on the patient's requirement or on the physicians recommendation by prescription. The costs are covered by the health insurances.

"ESYSTA, the first validated plug and play diabetes management system, that uses a transmitting insulin pen, which automatically transfers the data, is already available on the market and is reimbursed by health insurances. The addition of a Bluetooth-based insulin pen enables the expansion of the target group of type 1 and type 2 diabetics to those who would like to have mobile access to their insulin data.“, says Dr. Klaus Stöckemann, Peppermint Venture Partners and chairman of the Emperra advisory board.

The ESYSTA^® app: the novelty

The ESYSTA^® App, that can read data like date, time and injected amount of insulin, but also differentiate between injected insulin and insulin used for priming, is also suitable for Bluetooth blood glucose meters of other known manufacturers. The app will of course be able to transfer all generated therapy data automatically to the ESYSTA^® portal, in order to have the complete range of the ESYSTA^® portal services, like the simple representation of metabolic situations by a traffic light function, as well as clearly structured diagram profiles for blood glucose and insulin applications, to its disposal. Secure access by the attending physicians, the care staff or perhaps the relatives is integrated here. In order to offer a comprehensive therapy concept, the app is also aimed at acquiring manual data to complete the monitoring.

Source: http://www.emperra.com/